MedTrace Logo

Salivary microRNA in Endometriosis: Correlation With Response to Progestin Therapy

NCT06414720 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2025-04-02

No results posted yet for this study

Summary

This study aims to analyze the salivary miRNA specific for patients diagnosed with endometriosis, specifically evaluating the miRNA profile of patients who respond versus those who do not respond to progestin therapy. Ninety patients attending the Chronic Pelvic Pain Clinic will be recruited, and they will be asked to provide a saliva sample before starting medical therapy. The response to the therapy will be evaluated after 4 months from the beginning of the therapy itself.

Conditions

  • Endometriosis

Interventions

DRUG

Dienogest 2 MG

The patients will be started on progestin therapy after a saliva sample is collected from them for miRNA analysis.

Sponsors & Collaborators

  • University of Udine

    lead OTHER

Principal Investigators

  • Giuseppe Vizzielli, prof · University of Udine

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-22
Primary Completion
2025-12-01
Completion
2025-12-01

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06414720 on ClinicalTrials.gov